Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Graham Ross

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Annals of Clinical Biochemistry|October 20, 2009
Critical difference calculations revised: inclusion of variation in standard deviation with analyte concentrationGraham Ross Dallas Jones
Clinical Chemistry and Laboratory Medicine|May 9, 2026
Limitations to the development of Milan model 1b analytical performance specificationsGraham Ross Dallas Jones
Practical Laboratory Medicine|June 7, 2022
The effect of acute changes in glomerular filtration rate on common biochemical testsGraham Ross Dallas Jones, Jason Zhi Yong Chung
Pathology|May 1, 2016
Safe reading of chemical pathology reports: the RCPAQAP Report Assessment SurveySabrina Koetsier, Graham Ross Dallas Jones, Tony Badrick
Clinical Biochemistry|May 16, 2015
Effect of renal function on serum cardiac troponin T--Population and individual effectsJason Zhi Yong Chung, Graham Ross Dallas Jones
The Journal of Foot and Ankle Surgery : Official Publication of the American College of Foot and Ankle Surgeons|July 21, 2015
Weightbearing Radiographs Facilitate Functional Treatment of Ankle Fractures of Uncertain StabilityGraham Ross Hastie, Sabeen Akhtar, Usman Butt, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 5, 2013
Evidence-based approach to harmonised reference intervalsGus Koerbin, Ken Andrew Sikaris, Graham Ross Dallas Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancerJosé Baselga, Javier Cortés, Seock-Ah Im, et al.
Clinical Lung Cancer|May 22, 2012
A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancerEnriqueta Felip, Malcolm Ranson, Susana Cedrés, et al.
Breast Cancer Research and Treatment|October 17, 2013
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)David Miles, José Baselga, Dino Amadori, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Annals of Clinical Biochemistry|October 20, 2009
Critical difference calculations revised: inclusion of variation in standard deviation with analyte concentrationGraham Ross Dallas Jones
Clinical Chemistry and Laboratory Medicine|May 9, 2026
Limitations to the development of Milan model 1b analytical performance specificationsGraham Ross Dallas Jones
Practical Laboratory Medicine|June 7, 2022
The effect of acute changes in glomerular filtration rate on common biochemical testsGraham Ross Dallas Jones, Jason Zhi Yong Chung
Pathology|May 1, 2016
Safe reading of chemical pathology reports: the RCPAQAP Report Assessment SurveySabrina Koetsier, Graham Ross Dallas Jones, Tony Badrick
Clinical Biochemistry|May 16, 2015
Effect of renal function on serum cardiac troponin T--Population and individual effectsJason Zhi Yong Chung, Graham Ross Dallas Jones
The Journal of Foot and Ankle Surgery : Official Publication of the American College of Foot and Ankle Surgeons|July 21, 2015
Weightbearing Radiographs Facilitate Functional Treatment of Ankle Fractures of Uncertain StabilityGraham Ross Hastie, Sabeen Akhtar, Usman Butt, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 5, 2013
Evidence-based approach to harmonised reference intervalsGus Koerbin, Ken Andrew Sikaris, Graham Ross Dallas Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancerJosé Baselga, Javier Cortés, Seock-Ah Im, et al.
Clinical Lung Cancer|May 22, 2012
A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancerEnriqueta Felip, Malcolm Ranson, Susana Cedrés, et al.
Breast Cancer Research and Treatment|October 17, 2013
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)David Miles, José Baselga, Dino Amadori, et al.
Pageof 4